Related Experiment Video
Updated: Jul 10, 2026
Measuring the Carotid to Femoral Pulse Wave Velocity (Cf-PWV) to Evaluate Arterial Stiffness
Published on: May 3, 2018
[Arterial stiffness in hypopituitary patients with life-long growth hormone deficiency]
Jerzy Kosowicz1, Ziad El Ali, Andrzej Wykretowicz
1Katedra i Klinika Endokrynologii i Przemiany Materii, Uniwersytet Medyczny im. Karola Marcinkowskiego, Poznań. jkosowicz@poczta.fm
Introduction:
Patients with hypopituitarism have a shorter survival period from and premature mortality due to cardiovascular complications.
Objectives:
The aim of our study was to evaluate the arterial stiffness and hemodynamic parameters based on pulse wave analysis in 22 adult patients with long-life growth hormone (GH) and insulin-like factor I (IGF-I) deficiencies, lasting from 22 to 57 years.
Patients And Methods:
In all patients, a combined pituitary hormone deficiency was diagnosed. All patients were on substitution therapy, receiving levothyroxine, sex hormones and hydrocortisone (when required), but none of the patients had ever received recombinant GH therapy. A control group consisted of 36 healthy subjects strictly matched to patients by age and body mass index. In the patients and control subjects pulse wave analysis was performed with the use of Sphigmocor MX reconstructing the aortic pulse wave in a real time.
Results:
The peripheral and central augmentation indexes were significantly increased in the hypopituitary patients compared with the control subjects. The central pulse pressure was also elevated in the patients. These hemodynamic parameters pointed to an increased arterial stiffness.
Conclusions:
In patients with hypopituitarism, the life-long GH and IGF-I deficiencies lead to an increase in the arterial stiffness.
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...